Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Kadlec Hematology & Oncology
1856
mi
from 43215
Kennewick, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Kadlec Hematology & Oncology
1856
mi
from 43215
Kennewick, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Skagit Valley Hospital Cancer Care Center
2007
mi
from 43215
Mount Vernon, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Skagit Valley Hospital Cancer Care Center
2007
mi
from 43215
Mount Vernon, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Harrison Poulsbo Hematology and Onocology
2021
mi
from 43215
Poulsbo, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Harrison Poulsbo Hematology and Onocology
2021
mi
from 43215
Poulsbo, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
University of Washington; UW Medical Center
1982
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
1982
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
University Cancer Center at University of Washington Medical Center
1982
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
University Cancer Center at University of Washington Medical Center
1982
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Swedish Cancer Center
2005
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Swedish Cancer Center
2005
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Polyclinic First Hill
2005
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Polyclinic First Hill
2005
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Group Health Capitol Hill Campus
2006
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Group Health Capitol Hill Campus
2006
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Minor and James Medical, PLLC
2006
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Minor and James Medical, PLLC
2006
mi
from 43215
Seattle, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Cancer Care Northwest - Spokane South
1777
mi
from 43215
Spokane, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest - Spokane South
1777
mi
from 43215
Spokane, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Evergreen Hematology & Oncology
1778
mi
from 43215
Spokane, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Evergreen Hematology & Oncology
1778
mi
from 43215
Spokane, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Wenatchee Valley Medical Center
1912
mi
from 43215
Wenatchee, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
1912
mi
from 43215
Wenatchee, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Rocky Mountain Oncology
1217
mi
from 43215
Casper, WY
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
1217
mi
from 43215
Casper, WY
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Welch Cancer Center
1261
mi
from 43215
Sheridan, WY
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
1261
mi
from 43215
Sheridan, WY
Quality of Life and Symptom Management in Patients With Bladder Cancer
A Qualitative Study of Patients With Non-Invasive Bladder Cancer
Status: Archived
Dan L. Duncan Cancer Center at Baylor College of Medicine
995
mi
from 43215
Houston, TX
Quality of Life and Symptom Management in Patients With Bladder Cancer
A Qualitative Study of Patients With Non-Invasive Bladder Cancer
Status: Archived
Updated: 1/1/1970
Dan L. Duncan Cancer Center at Baylor College of Medicine
995
mi
from 43215
Houston, TX
Quality of Life and Symptom Management in Patients With Bladder Cancer
A Qualitative Study of Patients With Non-Invasive Bladder Cancer
Status: Archived
Veterans Affairs Medical Center - Houston
995
mi
from 43215
Houston, TX
Quality of Life and Symptom Management in Patients With Bladder Cancer
A Qualitative Study of Patients With Non-Invasive Bladder Cancer
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - Houston
995
mi
from 43215
Houston, TX
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia
Status: Archived
University of Chicago
270
mi
from 43215
Chicago, IL
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
University of Chicago
270
mi
from 43215
Chicago, IL
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
University of Alabama, Birmingham/Department of OB/GYN
492
mi
from 43215
Birmingham, AL
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
University of Alabama, Birmingham/Department of OB/GYN
492
mi
from 43215
Birmingham, AL
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
University of Colorado, Boulder
1179
mi
from 43215
Boulder, CO
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
1179
mi
from 43215
Boulder, CO
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Roswell Park Cancer Center Institute
288
mi
from 43215
Buffalo, NY
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
288
mi
from 43215
Buffalo, NY
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
640
mi
from 43215
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
640
mi
from 43215
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Children's Hospital at Downstate
481
mi
from 43215
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
481
mi
from 43215
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Cancer Institute of New Jersey at Hamilton
442
mi
from 43215
Trenton, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Updated: 1/1/1970
Cancer Institute of New Jersey at Hamilton
442
mi
from 43215
Trenton, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Mountainside Hospital
467
mi
from 43215
Montclair, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Updated: 1/1/1970
Mountainside Hospital
467
mi
from 43215
Montclair, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Updated: 1/1/1970
Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
453
mi
from 43215
New Brunswick, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
453
mi
from 43215
New Brunswick, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Overlook Hospital
453
mi
from 43215
Morristown, NJ
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
Status: Archived
Updated: 1/1/1970
Overlook Hospital
453
mi
from 43215
Morristown, NJ
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Status: Archived
Darien Pediatric Associates
506
mi
from 43215
Darien, CT
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
506
mi
from 43215
Darien, CT
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Status: Archived
Pfizer Investigational Site
239
mi
from 43215
Bristol, TN
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
239
mi
from 43215
Bristol, TN
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.
Status: Archived
Lifespan Hospitals
619
mi
from 43215
Providence, RI
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.
Status: Archived
Updated: 1/1/1970
Lifespan Hospitals
619
mi
from 43215
Providence, RI
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Status: Archived
The Cancer Institute of New Jersey (CINJ)
453
mi
from 43215
New Brunswick, NJ
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Status: Archived
Updated: 1/1/1970
The Cancer Institute of New Jersey (CINJ)
453
mi
from 43215
New Brunswick, NJ
Childhood Cancer Survivor Survey
Needs Assessment Survey in Childhood Cancer Survivors and Their Parents
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Childhood Cancer Survivor Survey
Needs Assessment Survey in Childhood Cancer Survivors and Their Parents
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memoral Sloan Kettering Cancer Center at Phelps
487
mi
from 43215
Sleepy Hollow, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memoral Sloan Kettering Cancer Center at Phelps
487
mi
from 43215
Sleepy Hollow, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memorial Sloan Kettering Rockville Centre
496
mi
from 43215
Rockville Centre, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering Rockville Centre
496
mi
from 43215
Rockville Centre, NY
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Moores Cancer Center
1926
mi
from 43215
La Jolla, CA
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
1926
mi
from 43215
La Jolla, CA
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
University of Chicago
270
mi
from 43215
Chicago, IL
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Updated: 1/1/1970
University of Chicago
270
mi
from 43215
Chicago, IL
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Dana Faber Cancer Institute
643
mi
from 43215
Boston, MA
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Updated: 1/1/1970
Dana Faber Cancer Institute
643
mi
from 43215
Boston, MA
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Nevada Cancer Institute
1767
mi
from 43215
Las Vegas, NV
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Updated: 1/1/1970
Nevada Cancer Institute
1767
mi
from 43215
Las Vegas, NV
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Memorial Sloan Kettering
480
mi
from 43215
New York City, NY
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering
480
mi
from 43215
New York City, NY